Damora Therapeutics, Inc. last reported quarterly results on Mar 10, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): diluted EPS of -$135.76. It usually reports 5–69 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 5–69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Mar 10, 2026
69 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-201
-2877.8%
|
-135.76
-2542.9%
|
|
Jan 6, 2023
6 days after quarter end
|
—
ended Dec 31, 2022
|
—
|
—
|
—
|
|
Jan 5, 2021
5 days after quarter end
|
—
ended Dec 31, 2020
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1800315
- Former names
- Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.